These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28922362)

  • 1. Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer.
    Pattison S; Mitchell C; Lade S; Leong T; Busuttil RA; Boussioutas A
    PLoS One; 2017; 12(9):e0183891. PubMed ID: 28922362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
    Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
    Omura T; Shimada Y; Nagata T; Okumura T; Fukuoka J; Yamagishi F; Tajika S; Nakajima S; Kawabe A; Tsukada K
    Oncol Rep; 2014 Feb; 31(2):613-8. PubMed ID: 24317477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
    Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
    Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
    Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
    J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer.
    Kim SG; Hwang SH
    World J Surg Oncol; 2016 Apr; 14():102. PubMed ID: 27039375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis.
    Cao J; Qi F; Liu T
    Scand J Gastroenterol; 2014 Jun; 49(6):690-704. PubMed ID: 24731211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does adjuvant radiotherapy benefit patients with diffuse-type gastric cancer? Results from the Surveillance, Epidemiology, and End Results database.
    Stessin AM; Sison C; Schwartz A; Ng J; Chao CK; Li B
    Cancer; 2014 Nov; 120(22):3562-8. PubMed ID: 25043858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The patterns and timing of recurrence after curative resection for gastric cancer in China.
    Liu D; Lu M; Li J; Yang Z; Feng Q; Zhou M; Zhang Z; Shen L
    World J Surg Oncol; 2016 Dec; 14(1):305. PubMed ID: 27931221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
    Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
    Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
    Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
    Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
    J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extended Pathohistological Criteria for Assessment of the Long-Term Prognosis of Gastric Cancer].
    Dittmar Y; Rauchfuss F; Dondorf F; Ardelt M; Scheuerlein H; Settmacher U
    Zentralbl Chir; 2016 Aug; 141(4):433-41. PubMed ID: 25723861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with early recurrence after curative surgery for gastric cancer.
    Kang WM; Meng QB; Yu JC; Ma ZQ; Li ZT
    World J Gastroenterol; 2015 May; 21(19):5934-40. PubMed ID: 26019458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
    Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
    J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients.
    Qiu M; Zhou Y; Zhang X; Wang Z; Wang F; Shao J; Lu J; Jin Y; Wei X; Zhang D; Wang F; Li Y; Yang D; Xu R
    BMC Cancer; 2014 Nov; 14():823. PubMed ID: 25380654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
    Kim S; Lim DH; Lee J; Kang WK; MacDonald JS; Park CH; Park SH; Lee SH; Kim K; Park JO; Kim WS; Jung CW; Park YS; Im YH; Sohn TS; Noh JH; Heo JS; Kim YI; Park CK; Park K
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1279-85. PubMed ID: 16099596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods.
    Kim DH; Kim SM; Hyun JK; Choi MG; Noh JH; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Jul; 20(7):2317-27. PubMed ID: 23677605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.